Keryx Board Absolutely Supports Alliance with Akebia and Encourages Stockholders to vote “FOR” the Alliance Proposals
Keryx Special Affair of Stockholders Appointed for December 11, 2018
BOSTON, Oct. 30, 2018 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today appear that it and Akebia Therapeutics, Inc. (NASDAQ: AKBA) accept filed absolute proxy abstracts with the U.S. Balance and Exchange Commission (“SEC”) in affiliation with their corresponding Special Meetings of Stockholders that accept been alleged to accept the ahead appear proposed alliance of Keryx and Akebia. The absolute collective proxy account is accessible on the Investor Relations area of Keryx’s website, as able-bodied as www.sec.gov, and will be mailed to all Keryx accepted stockholders advantaged to vote at the Special Meeting.
Keryx’s Special Affair of Stockholders is appointed to booty abode on December 11, 2018 at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 at 11:00 a.m. Eastern Time. All Keryx accepted stockholders of almanac as of the aing of business on October 22, 2018 will be advantaged to vote their shares either in being or by proxy at the Special Meeting.
“The Keryx Board is agog and accepted in its abutment of the Akebia alliance and believes this transaction maximizes amount for Keryx stockholders,” said Michael W. Rogers, Chairman of the Keryx Board of Directors. “We animate our stockholders to vote their shares in favor of this transformational merger, which creates a renal-focused aggregation with a allegation to developing and carrying avant-garde ameliorative products.”
The Keryx Board absolutely recommends that Keryx stockholders vote “FOR” the merger-related proposals included in the absolute collective proxy statement.
If you accept any questions, crave abetment with voting your proxy card, or allegation added copies of the proxy materials, amuse contact:
Georgeson 1290 Avenue of the Americas, 9th FloorNew York, NY 10104Toll-Free: (888) 680-1525
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of avant-garde medicines that accommodate different and allusive advantages to bodies with branch disease. The Keryx aggregation works with affection to beforehand the affliction of bodies with this circuitous disease. This adherence has resulted in two FDA-approved break for Keryx’s aboriginal medicine, Auryxia (ferric citrate) tablets. For added advice about Keryx, amuse appointment www.keryx.com.
Additional Advice and Where to Find It
In affiliation with the proposed merger, Akebia has filed with the SEC a Registration Account on Form S-4, which, as amended, includes a final advertisement with account to the shares of Akebia’s accepted banal to be issued in the proposed alliance and a absolute collective proxy account of Keryx and Akebia with account to the proposed merger. The Registration Account was declared able by the SEC on October 30, 2018 and the absolute collective proxy account was mailed or contrarily fabricated accessible to Keryx’s and Akebia’s corresponding stockholders on or about October 31, 2018. BEFORE MAKING ANY VOTING DECISION, AKEBIA’S AND KERYX’S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF AKEBIA AND KERYX WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and stockholders will be able to access a chargeless archetype of the collective proxy statement/prospectus and added abstracts absolute important advice about Akebia and Keryx, with the SEC, through the website maintained by the SEC at www.sec.gov. Akebia and Keryx accomplish accessible chargeless of allegation at www.akebia.com and www.keryx.com, appropriately (in the “Investors” section), copies of abstracts they book with, or accouter to, the SEC.
Participants in the Solicitation
Akebia, Keryx and their corresponding directors, controlling admiral and assertive advisers and added bodies may be accounted to be participants in the address of proxies from the stockholders of Akebia and Keryx in affiliation with the proposed merger. Security holders may access advice apropos the names, affiliations and interests of Akebia’s admiral and admiral in Akebia’s Anniversary Report on Form 10-K for the budgetary year concluded December 31, 2017, which was filed with the SEC on March 12, 2018 and its absolute proxy account for the 2018 anniversary affair of stockholders, which was filed with the SEC on April 30, 2018. Security holders may access advice apropos the names, affiliations and interests of Keryx’s admiral and admiral in Keryx’s Anniversary Report on Form 10-K for the budgetary year concluded December 31, 2017, which was filed with the SEC on February 21, 2018, and the Amendment No. 1 on Form 10-K/A, which was filed with the SEC on April 30, 2018, and its absolute proxy account for the 2018 anniversary affair of stockholders, which was filed with the SEC on May 31, 2018. To the admeasurement the backing of Akebia’s balance by Akebia’s admiral and controlling admiral or the backing of Keryx balance by Keryx’s admiral and controlling admiral accept afflicted back the amounts set alternating in Akebia’s or Keryx’s corresponding proxy account for its 2018 anniversary affair of stockholders, such changes accept been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Added advice apropos the interests of such individuals in the proposed alliance are included in the collective proxy statement/prospectus apropos to the proposed alliance that was filed with the SEC. These abstracts may be acquired chargeless of allegation from the SEC’s website at www.sec.gov, Akebia’s website at www.akebia.com and Keryx’s website at www.keryx.com.
This certificate does not aggregate a address of proxy, an action to acquirement or a address of an action to advertise any securities.
This certificate contains advanced statements aural the acceptation of the federal balance law. Such statements are based aloft accepted plans, estimates and expectations that are accountable to assorted risks and uncertainties. The admittance of advanced statements should not be admired as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “create,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “position,” “predict,” “potential,” “opportunity” and words and agreement of agnate actuality acclimated in affiliation with any altercation of approaching plans, accomplishments or contest analyze advanced statements. All statements, added than absolute facts, including statements apropos the adeptness of the parties to complete the alliance because the assorted closing conditions; the cleanup of the alliance and the abeyant allowances of the alliance are advanced attractive statements. Important factors that could account absolute after-effects to alter materially from Akebia’s and Keryx’s plans, estimates or expectations could include, but are not bound to: (i) Akebia or Keryx may be clumsy to access stockholder approval as appropriate for the merger; (ii) altitude to the closing of the alliance may not be satisfied; (iii) the alliance may absorb abrupt costs, liabilities or delays; (iv) the aftereffect of the advertisement of the alliance on the adeptness of Akebia or Keryx to absorb and appoint key cadre and advance relationships with customers, suppliers and others with whom Akebia or Keryx does business, or on Akebia’s or Keryx’s operating after-effects and business generally; (v) Akebia’s or Keryx’s corresponding businesses may ache as a aftereffect of ambiguity surrounding the alliance and disruption of management’s absorption due to the merger; (vi) the aftereffect of any acknowledged affairs accompanying to the merger; (vii) Akebia or Keryx may be abnormally afflicted by added economic, business, and/or aggressive factors; (viii) the accident of any event, change or added affairs that could accord acceleration to the abortion of the alliance agreement; (ix) risks that the alliance disrupts accepted affairs and operations and the abeyant difficulties in agent assimilation as a aftereffect of the merger; (x) the accident that Akebia or Keryx may be clumsy to access authoritative and authoritative approvals appropriate for the transaction, or that appropriate authoritative and authoritative approvals may adjournment the transaction or aftereffect in the artifice of altitude that could abate the advancing allowances from the proposed transaction or account the parties to carelessness the proposed transaction; (xi) risks that the advancing allowances of the alliance or added bartering opportunities may contrarily not be absolutely accomplished or may booty best to apprehend than expected; (xii) the appulse of legislative, regulatory, aggressive and abstruse changes, including the contempo changes to agreement advantage for Auryxia that could accept a actual adverse aftereffect on Auryxia sales and profitability; (xiii) expectations for approaching analytic trials, the timing and abeyant outcomes of analytic trials and interactions with authoritative authorities; and (xiv) added risks to the cleanup of the merger, including the accident that the alliance will not be consummated aural the accepted time aeon or at all. Added factors that may affect the approaching after-effects of Akebia and Keryx are set alternating in their corresponding filings with the SEC, including anniversary of Akebia’s and Keryx’s best afresh filed Anniversary Report on Form 10-K, consecutive Quarterly Reports on Form 10-Q, Accepted Reports on Form 8-K, in the absolute collective proxy statement/prospectus filed by Akebia and Keryx and added filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. See in accurate “Risk Factors” in the collective proxy statement/prospectus, Item 1A of Akebia’s Quarterly Report on Form 10-Q for the division concluded June 30, 2018 beneath the branch “Risk Factors” and Item 1A of Keryx’s Quarterly Report on Form 10-Q for the division concluded June 30, 2018 beneath the branch “Risk Factors.” The risks and uncertainties declared aloft and in Akebia’s best contempo Quarterly Report on Form 10-Q and Keryx’s best contempo Quarterly Report on Form 10-Q are not absolute and added advice apropos Akebia and Keryx and their corresponding businesses, including factors that potentially could materially affect their corresponding businesses, banking action or operating results, may appear from time to time. Readers are apprenticed to accede these factors anxiously in evaluating these advanced statements, and not to abode disproportionate assurance on any advanced statements. Readers should additionally anxiously analysis the accident factors declared in added abstracts that Akebia and Keryx book from time to time with the SEC. The advanced statements in these abstracts allege alone as of the date of these materials. Except as appropriate by law, Akebia and Keryx accept no obligation to amend or alter these advanced statements for any reason, alike if new advice becomes accessible in the future.
12 Great Free Copy Of Will Forms Ideas That You Can Share With Your Friends | Free Copy Of Will Forms – free copy of will forms
| Delightful to help our blog, with this period We’ll provide you with concerning free copy of will forms